BellBrook Labs offers informational application notes for our various Transcreener products. These notes provide a protocol and experimental sample for the use of the respective Transcreener assay to measure enzyme activity, screen compound libraries, profile inhibitors, measure residence time, and more!
Interested in ordering an assay kit? Check out our Ordering Information page for pricing and shipping details.
This Application Note provides a protocol and experimental example for the use of the Transcreener® ADP² FP Assay to determine the residence time of a drug (or drug candidate) during its interaction with a kinase.
This Application Note describes how to streamline the process of inhibitor profiling with the Transcreener ADP² FP Assay by eliminating the need to experimentally optimize the ADP² Antibody concentration and the need for a standard curve.
This Application Note provides a protocol and example on how to use the Transcreener® ADP² FP Assay to experimentally determine the KM value of Kemptide and ATP with Protein Kinase A (PKA) Enzyme.
This Application Note describes running Transcreener’s ADP² Assay in kinetic mode. This method reduces the number of experiments required to optimize conditions for a new enzyme. Running assays in real-time save on the cost of reagents and provides a check on assay linearity.
This Application Note describes methods for using the Transcreener ADP² Kinase Assay to measure ADK enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Kinase Assay to measure BTK enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Kinase Assay to measure MAPK1 enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Kinase Assay to measure MAPK8 enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Kinase Assay to measure PKR enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Kinase Assay to measure RIPK1 enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Kinase Assay to measure RIPK2 enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Kinase Assay to measure TYK2 enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² ATPase Assay to measure VPS4a enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² ATPase Assay to measure VPS4b enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² ATPase Assay to measure BLM Helicase enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Kinase Assay to measure PLK1 enzymatic activity in a high-throughput format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Assay to measure SMARCAL1 enzymatic activity in a high-throughput format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Kinase Assay to measure IRE1a enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes methods for using the Transcreener ADP² Assay to measure NAMPT enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes how the RGScreen platform uses proprietary G alpha protein variants with altered GTP hydrolysis & GDP dissociation rates that enable detection of RGS GAP activity using the Transcreener GDP Assay.
This application note describes methods for using the AptaFluor SAH Methyltransferase Assay to measure METTL3/METTL14 enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This application note describes methods for using the AptaFluor SAH Methyltransferase Assay to measure PRMT5 enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This application note describes methods for using the AptaFluor SAH Methyltransferase Assay to measure MLL4 enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This application note describes methods for using the AptaFluor SAH Methyltransferase Assay to measure NSP14 enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This application note describes methods for using the AptaFluor SAH Methyltransferase Assay to measure NNMT enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note describes how to generate a dose response curve for an inhibitor using a Transcreener EPIGEN Assay kit. The general protocol shows how to set up an experiment to run dose response curves using Sinefungin as an example for HMT SET7/9 to determine the IC50 value.
This Application Note describes how to determine Z’, the statistical parameter used to measure HTS quality, using a Transcreener EPIGEN Methyltransferase Assay kit. The general protocol shows how to set up an experiment to determine Z’ value, using HMT PRMT3 as an example.
This Application Note will serve as a guide for using the Transcreener EPIGEN Methyltransferase Assay to detect the initial velocity enzyme activity of HMT G9a with an assay window suitable for inhibitor screening and dose response measurements.
This Application Note will serve as a guide for using the Transcreener EPIGEN Methyltransferase Assay to detect the initial velocity enzyme activity of HMT SET7/9 with an assay window suitable for inhibitor screening and dose response measurements.
This Application Note will serve as a guide for using the Transcreener EPIGEN Methyltransferase Assay to detect the initial velocity enzyme activity of HMT SET8 with an assay window suitable for inhibitor screening and dose response measurements.
This Application Note will serve as a guide for using the Transcreener EPIGEN Methyltransferase Assay to detect the initial velocity enzyme activity of HMT PRMT1 with an assay window suitable for inhibitor screening and dose response measurements.
This Application Note will serve as a guide for using the Transcreener EPIGEN Methyltransferase Assay to detect the initial velocity enzyme activity of HMT PRMT3 with an assay window suitable for inhibitor screening and dose-response measurements.
This application note describes methods for using the Transcreener dAMP FP Assay to measure WRN exonuclease enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This application note describes methods for using the Transcreener dAMP FP Assay to measure APE2 exonuclease enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This application note describes methods for using the Transcreener ADPR FP Assay to measure SARM1 enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This Application Note provides the optimal instrument parameters used to validate the BMG Labtech CLARIOstar Microplate Readers with Transcreener’s ADP2 TR-FRET Assay & Transcreener’s AMP2/GMP2 TR-FRET Assay.
This application note demonstrates how to analyze data utilizing GraphPad Prism software. It walks through the transformation, interpolation, and plotting of data generated during drug screening and inhibitor dose response profiling.
This application note demonstrates how to use the Transcreener Assay in 1536-well formats. It discusses scaling to miniturized formats and plate reader settings necessary to achieve assay success.
This application note demonstrates how to use Transcreener Assays for uncovering activators while screening.
This application note describes methods for using the Transcreener AMP²/GMP² FP Assay to measure ENPP3 enzymatic activity in a high throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
This application note describes methods for using the Transcreener AMP²/GMP² FP Assay to measure XRN1 enzymatic activity in a high-throughput (384-well) format, e.g., for inhibitor screening and/or inhibitor dose-response measurements.
BellBrook Labs
1232 Fourier Drive, Suite 115
Madison, Wisconsin 53717 USA
(608) 443-2400
info@bellbrooklabs.com